World first clinical trial of medicinal cannabis for aggressive brain cancer

Bite worked with BioCeuticals to launch the world’s first clinical trial on medicinal cannabis as a treatment for aggressive brain cancer.

Our role was to drive shareholder value by raising awareness of BioCeuticals’ funding of the trial, positioning the brand at the cutting edge of alternative medicine. 

We needed to needed to create a media program that navigated the availability of stakeholders and the sensitivity of working with trial participants with terminal cancer at the end of their treatment options. 

Our solution was to focus on a television exclusive, working with trial lead Professor Charlie Teo and a trial participant, and then to use that as the launch pad from which to rollout the rest of the media relations program.

We secured an exclusive on Channel 9 News supported by  more than 130 media stories across television, print, radio and online news outlets providing +5.4 million opportunities to highlight BioCeuticals’ involvement in the trial to Australians.